SEATTLE, Aug. 2 /PRNewswire/ -- "The federal government's ability to
more exactly measure the number of new HIV infections in the United States
annually is a great statistical tool -- but that is all that it is. I
interpret the new numbers this way: They remind us that HIV/AIDS continues
to be a real public health problem in this country as well as in many
developing nations around the globe. Despite recent setbacks in developing
an effective vaccine to prevent HIV infection, I believe that a vaccine is
our most promising weapon against new infections. The research community's
commitment to find a vaccine must not waver."
Dr. Corey is the Principal Investigator of the HIV Vaccine Trials
Network (HVTN) and co-director of the Vaccine and Infectious Diseases
Institute, both at Fred Hutchinson Cancer Research Center in Seattle, WA.
About the HIV Vaccine Trials Network
The HVTN is an international collaboration of scientists and
institutions whose goal is to accelerate the search for an HIV vaccine by
sharing trial results and facilitating parallel, concurrent testing. The
HVTN is a unique hybrid that combines the depth and diversity of the
academic community and the flexibility of a commercial drug company.
Working with industry and government, the HVTN seeks to expedite and
coordinate the trial process, advancing vaccine candidates and building a
body of knowledge about HIV vaccine trials. The HVTN is supported through a
cooperative agreement with the National Institute of Allergy and Infectious
Diseases, which is a component of the U.S. National Institutes of Health.
The Network and NIAID have a close, cooperative working relationship, with
shared attention to the intellectual and scientific issues.
Contact: Sarah Alexander
206-910-3801
salex@hvtn.org
SOURCE HIV Vaccine Trials Network
 back to top
Related links:
http://www.fhcrc.org
CONTACT:
Sarah Alexander of HIV Vaccine Trials
Network, +1-206-910-3801, salex@hvtn.org
|
